

Topical treatment of melanoma skin metastases with Im

Dermatology Online Journal

21,

DOI: 10.5070/d3212023034

Citation Report

#	ARTICLE	IF	CITATIONS
1	Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK. <i>European Journal of Dermatology</i> , 2016, 26, 477-486.	0.3	1
2	Intralesional treatment of metastatic melanoma: a review of therapeutic options. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 647-656.	2.0	34
3	TLR7 agonist in combination with <i>Salmonella</i> as an effective antimelanoma immunotherapy. <i>Immunotherapy</i> , 2018, 10, 665-679.	1.0	12
4	Immunobiological efficacy and immunotoxicity of novel synthetically prepared fluoroquinolone ethyl 6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate. <i>Immunobiology</i> , 2018, 223, 81-93.	0.8	7
5	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2019, , 1-28.		0
6	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1107-1119.	1.3	11
7	Topical and intralesional therapies for in-transit melanoma. <i>Melanoma Management</i> , 2019, 6, MMT23.	0.1	4
8	Management of local or regional non-nodal disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 187-199.	0.8	8
9	Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy. <i>Investigational New Drugs</i> , 2020, 38, 662-674.	1.2	31
10	Non-Operative Options for Loco-regional Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 631-642.	0.7	1
11	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2020, , 867-894.		3
12	Melanoma in situ mimicking a Lichen planus-like keratosis. <i>Acta Biomedica</i> , 2018, 88, 496-498.	0.2	3
13	Soluble Factors and Receptors Involved in Skin Innate Immunity—What Do We Know So Far?. <i>Biomedicines</i> , 2021, 9, 1795.	1.4	4
14	Management of In-Transit Metastases. <i>Current Oncology Reports</i> , 2022, 24, 573.	1.8	0
15	Melanoma: An update on systemic therapies. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 515-524.	0.6	26
16	TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response. <i>Cytotechnology</i> , 0, , .	0.7	0
17	Laponite® gel formulation containing simvastatin for melanoma treatment. <i>Applied Clay Science</i> , 2022, 228, 106651.	2.6	1